Related Experiment Video

Updated: May 27, 2026

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Isoalantolactone protects against Staphylococcus aureus pneumonia

Jiazhang Qiu1, Mingjing Luo, Jianfeng Wang

  • 1Key Laboratory of Zoonosis, Ministry of Education, Institute of Zoonosis, College of Animal Science and Veterinary Medicine, Jilin University, Changchun, China.

FEMS Microbiology Letters
|November 19, 2011
PubMed

Insights

Isoalantolactone (IAL) does not kill Staphylococcus aureus but effectively inhibits its alpha-toxin production. This compound protects mice from S. aureus pneumonia, offering a novel therapeutic strategy.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Staphylococcus aureus infections are a growing concern due to antibiotic resistance.
  • Targeting bacterial virulence factors is a promising alternative therapeutic strategy.
  • Alpha-toxin is a key virulence factor essential for S. aureus pneumonia pathogenesis.

Purpose of the Study:

  • To investigate the anti-virulence potential of isoalantolactone (IAL) against Staphylococcus aureus.
  • To evaluate IAL's effect on alpha-toxin expression and its efficacy in a pneumonia model.

Main Methods:

  • Minimum Inhibitory Concentration (MIC) assay to determine anti-S. aureus activity.
  • In vitro assessment of IAL's impact on alpha-toxin expression.
  • In vivo mouse model of S. aureus pneumonia to evaluate therapeutic protection.

Main Results:

  • IAL exhibited no significant in vitro anti-S. aureus activity based on MIC values.
  • IAL markedly inhibited alpha-toxin expression in S. aureus at low concentrations.
  • IAL treatment demonstrated significant protection in mice challenged with S. aureus pneumonia.

Conclusions:

  • Isoalantolactone is a potent inhibitor of Staphylococcus aureus alpha-toxin expression.
  • IAL represents a potential therapeutic agent for treating S. aureus infections, particularly pneumonia, by targeting virulence rather than bacterial growth.

More Related Videos

Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds06:36

Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds

Published on: September 8, 2021

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: